SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Clinical Part:
The objective of this study is to determine the efficacy and safety of SUTENT in patients
with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of
intracranial glioblastoma multiforme, above 18 years of age and of both genders, who have a
first tumor recurrence or progress after surgery, radiation- and chemotherapy will be
included. The hypothesis is that SUTENT will significantly increase the progression free
survival rate at 6 months in the study population.